MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma
نویسندگان
چکیده
منابع مشابه
Primary cutaneous marginal zone B-cell lymphoma.
Primary cutaneous marginal zone B-cell lymphoma (PCMZL) is included as one of the major types of primary cutaneous B-cell lymphoma in the revised World Health Organization-European Organization for Research and Treatment of Cancer classification. Clinically, PCMZL is an indolent disease and has an excellent prognosis. PCMZL is composed of a polymorphous infiltrate that includes centrocyte-like,...
متن کاملPrimary cutaneous B-cell lymphoblastic lymphoma.
652 in dust and air, and this increased exposure can lead to a sensitization against this metal, even in very low doses, with risk of allergic reaction, especially in susceptible individuals. Several authors have described reactions both to nickel and palladium ions,[1-3] which has led to the thinking that the reaction is not dependent on the element itself but rather on the formation of comple...
متن کاملPrimary cutaneous large B cell lymphoma, leg type: A case report and review of the literature
Primary cutaneous large B-cell lymphoma leg type is a rare andaggressive neoplasm as defined by the recently updated WorldHealth Organization - European Organization for Research andTreatment of Cancer. We report a case of an 80-year-old manwith multiple cutaneous lesions. Here, we review the availableliterature and summarize clinical features and management ofthis type of cutaneous B-cell lymp...
متن کاملPrimary cutaneous CD30+T cell lymphoma: A case report
Primary cutaneous CD30+ T cell lymphoma is rare lymphoma originally in and confined to the skin. These lymphomas usually present as a large solitary and often ulcerated nodule. Its prognosis is a good and has a good response to radiotherapy. We report a 34- year- old man who had primary cutaneous CD30+T cell lymphoma on his face, which presented as an ulcerated nodule.
متن کاملBiological prognostic markers in diffuse large B-cell lymphoma.
BACKGROUND Multiple novel therapeutic options have emerged in the treatment of non-Hodgkin lymphoma, including monoclonal antibodies and different classes of biological agents. With this increased diagnostic sophistication, novel prognostic markers are needed to stratify patients according to risk factors, particularly those with a mechanistic underpinning, to provide the basis for individually...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Modern Pathology
سال: 2012
ISSN: 0893-3952,1530-0285
DOI: 10.1038/modpathol.2012.149